HER2+ | Real-World Evidence

01
SUMMARY 01Real-World Data Confirms T-DXd's Efficacy and Manageable Safety Across all HER2 Expression Levels

Real-world evidence shows that T-DXd delivers meaningful effectiveness across HER2-positive and HER2-low metastatic breast cancer, with longer treatment duration, improved survival outcomes, and clinically relevant responses alongside a generally manageable safety profile.

View full summary

T-DXd delivers significant effectiveness, medical summary infographic

Select View full summary again to close this image.

02
SUMMARY 02T-DM1 retains meaningful benefit in heavily pretreated, more complex real-world populations, supporting its role as a standard HER2-targeted option

Real-world findings indicate that T-DM1 remains a reliable and effective standard option for heavily pretreated and clinically complex HER2-positive metastatic breast cancer, particularly in later lines or when other therapies are unsuitable.

View full summary

T-DM1 benefits and recommended actions, medical summary infographic

Select View full summary again to close this image.

03
SUMMARY 03Tucatinib provides durable HER2+ mBC treatment persistence and meaningful rwTTD post-T-DXd for many with brain mets and multiple prior lines

Real-world evidence suggests that tucatinib-based therapy provides durable treatment persistence and meaningful real-world time to next treatment after T-DXd, including for patients with brain metastases and multiple prior lines of therapy.

View full summary

Tucatinib continued benefit, medical summary infographic

Select View full summary again to close this image.

04
SUMMARY 04Signals suggest earlier use of T-DXd may improve patient outcomes

Emerging real-world signals associate earlier T-DXd use with higher response rates, longer progression-free survival, and more durable benefit, supporting earlier sequencing for eligible patients together with proactive safety monitoring.

View full summary

Earlier use of T-DXd, medical summary infographic

Select View full summary again to close this image.

Estimated Treatment
‍Trends Across the Patient Journey

Estimated Treatment Adoption Progress

Estimated Treatment Adoption Progress

Estimated Treatment Adoption Progress

Understanding real-world evidence across HER2-positive breast cancer.

Evidence at a glance. Actions in focus.

Real-World Data Confirms T-DXd's Efficacy and Manageable Safety Across all HER2 Expression Levels

T-DM1 retains meaningful benefit in heavily pretreated, more complex real-world populations, supporting its role as a standard HER2-targeted option

Tucatinib provides durable HER2+ mBC treatment persistence and meaningful rwTTD post-T-DXd for many with brain mets and multiple prior lines

Signals suggest earlier use of T-DXd may improve patient outcomes

Real-world data. Clearer context.

Explore evidence

Access resources

Follow updates

Clear navigation

Estimated Treatment‍Trends Across the Patient Journey

Estimated Treatment Adoption Progress

Estimated Treatment Adoption Progress

Estimated Treatment Adoption Progress

Understanding real-world evidence across HER2-positive breast cancer.

Evidence at a glance. Actions in focus.

Real-World Data Confirms T-DXd's Efficacy and Manageable Safety Across all HER2 Expression Levels

T-DM1 retains meaningful benefit in heavily pretreated, more complex real-world populations, supporting its role as a standard HER2-targeted option

Tucatinib provides durable HER2+ mBC treatment persistence and meaningful rwTTD post-T-DXd for many with brain mets and multiple prior lines

Signals suggest earlier use of T-DXd may improve patient outcomes

Real-world data. Clearer context.

Explore evidence

Access resources

Follow updates

Clear navigation

Living Data Set

Estimated Treatment
‍Trends Across the Patient Journey